Research Capital launched coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with a “speculative buy” rating and price target of $10.30 (Canadian). The stock closed at $3.69 on Jan. 6. Eupraxia’s lead product, EP...
Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) released updated interim data from its Phase 2 pivotal trial with its key value driver, TLD-1433, activated by its proprietary TLC-3200 medical laser system, that Research...
Research Capital raised its price target for Valeo Pharma (CSE:VPH) to $1 (Canadian) from 70 cents and maintained a “speculative buy” rating after the company closed a $40-million (U.S.) non-dilutive financing from...
Research Capital downgraded Bellus Health (NASDAQ:BLU) to “hold” from “speculative buy” and removed its previous $14.50 price target so “we can properly account for the new dilution” from a $153-million offering of new...
Research Capital initiated coverage of Auxly Cannabis Group (TSX:XLY) with a “buy” rating and price target of 50 cents (Canadian). The stock closed at 23 cents on Sept. 29. Auxly’s strategy to focus on building the...
Research Capital initiated coverage of Aleafia Health (TSX:AH) with a “buy” rating and price target of 75 cents (Canadian). The stock closed at 36 cents on Sept. 21. “We believe that Aleafia’s revenue growth will be...
Research Capital initiated coverage of Perimeter Medical Imaging (TSXV:PINK) with a “speculative buy” rating and a 12-month price target of $4.90 (Canadian). The stock closed at $3.37 on June 28. Perimeter is a medical...